ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
32 hedge funds and large institutions have $7.54M invested in ImmunoCellular Therapeutics, Ltd. in 2015 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 2 closing their positions.
152% more capital invested
Capital invested by funds: $3M → $7.54M (+$4.54M)
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
3% more funds holding
Funds holding: 31 → 32 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.7M |
| 2 |
AC
Armistice Capital
New York
|
+$1.55M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.24M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$425K |
| 5 |
Renaissance Technologies
New York
|
+$214K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$99K |
| 2 |
CC
Callan Capital
La Jolla,
California
|
-$43.9K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$43K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$16.4K |
| 5 |
Morgan Stanley
New York
|
-$1.58K |
IMUC Hedge Fund Activity: Q1 2015 in Review
32 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q1 2015, worth a combined $7.54M — up 152% from $3M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IMUC positions and 2 closed out — a net gain of 1 holder — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $3.7M. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $99K sold.
- 32 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q1 2015, up from 31 in Q4 2014.
- Funds reported $7.54M of ImmunoCellular Therapeutics, Ltd. stock for Q1 2015, up 152% quarter-over-quarter.
- 3 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q1 2015 and 2 closed out, a net change of +1 holder.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q1 2015 was Sabby Management, an estimated $3.7M added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q1 2015 was Virtu KCG Holdings, an estimated $99K sold.
Based on aggregated 13F filings for Q1 2015.